The investment enhances Lonza’s capabilities and flexibility to support both clinical and commercial supply and will play a key role in meeting the growing market demand for bioconjugates
New facility is based at Lonza’s Bend, Oregon (US) site, a Center of Excellence for bioavailability enhancement
MindRank expects to initiate a Phase I safety study in the first quarter of 2023.
China is now focusing on establishing volume and enhancing capabilities for innovative high value drug production
Expanded capacity in Nansha, China will support mid-scale manufacturing to ensure a smooth transition between early-phase and large-scale commercial production
This is the second line opened this year for parenteral drug product clinical and commercial manufacturing, with an annual capacity of 10 million units
Innovative Capsugel Enprotect capsule can simplify the manufacturing process to accelerate drug development and expedite first-in-human timelines
Availability of pharmaceutical-grade materials with broad API compatibility key to advancing drug delivery solutions
Dr. Bunker will focus on leading Research and Development (R&D) in San Diego, advancing the preclinical pipeline and optimizing the Company’s Integrated Discovery Engine.
Phase 2 study to assess efficacy and safety of once daily linperlisib in patients with advanced peripheral T/NK cell lymphoma
Subscribe To Our Newsletter & Stay Updated
